Pharmacology

The main scientific directions of the department: Modeling and substantiation of approaches to the use of new pharmacological agents for various lesions of the central nervous system; Modeling and pharmacotherapy of chronic heart failure; Modeling and pharmacotherapy of liver lesions

We specialize in the early development of low molecular weight drugs and the development of probe molecules for the study of biological processes

Research interests = Creation of models of tumor growth (immunodeficient Balb/c nude mice, Danio rerio embryos, cultural models) and research on these models of antitumor activity and mechanisms of action of new agents = Master's program of the Department of Biochemistry of the RUDN "Creation and development of drugs" In a broad sense, the scientific interests of the laboratory are at the junction of experimental oncology, biochemistry and pharmacology. We help researchers in the field of medical chemistry, biotechnology and fundamental oncology to evaluate the effect of new agents on tumor growth (cytotoxic, antitumor effect) and to study certain aspects of the mechanisms of action of potential drugs

In vivo and in vitro studies of biologically active compounds. Pharmaceutical development.

The CAD Youth Laboratory was established in 2022 as part of the national project "Science and Universities" of the Russian Federation in the field of new medicine. A key vector in research is the search for new substances aimed at combating antimicrobial resistance.

Development of innovative medicines, conducting preclinical and registration studies of antiviral, immunostimulating and cytotoxic activity of chemotherapy drugs.

Investigation of the molecular and cellular mechanisms of action of drugs

Research in the field of psychoneuroendocrinology is actively developing. Hormonal status disorders are known to underlie behavioral and cognitive deficits in aging, Alzheimer's disease, menopausal and premenstrual syndrome in women. Based on the study of the interaction between the endocrine and neurotransmitter systems, drugs are being developed that combine the properties of hormones (estrogen, androgen) and neurotropic agents (agonist-antagonist of M1 acetylcholine receptors, 1A and 2A serotonin receptors, D1 and D2 dopamine receptors). The use of substances of this kind will make it possible to eliminate disorders in both the endocrine and neurotransmitter systems simultaneously, preventing the formation of a "vicious" circle. Molecular pathogenetic studies have shown violations of neuroendocrine transmission (steroid, thyroid hormones, biogenic amines and their metabolites), intracellular signal transduction (SC2 cascade) and receptor expression (1A- and 2A-serotonin receptors, 17b-estradiol) in cognitive disorders associated with estrogen deficiency and aging. An important section of psychoneuroendocrinological research is the study of the non-hormonal effects of hormones and hormone-like substances. Thus, pharmacological analysis using liberins, the tropic hormones of the pituitary gland, revealed the hormonal components of dependence on alcohol, opiates, psychostimulants and other narcogens. The possibility of blocking addictive behavior in animals by intrastructural administration of antagonists of corticoliberin, ghrelin, orexin and substance P, i.e. peptide hormones modulating emotional and motivational components of behavior, is shown. On this basis, a platform has been formulated for the creation of pharmacological drugs with an anti-narcotic effect.